Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone for NAFLD in Young Adults
NCT02726542Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- May 2017
- Primary completion
- Apr 2020
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of somatropin in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Hepatic Fat Fraction at 24 weeks. Started May 2017; status: completed.
02
Drugs
somatropin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02726542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726542.